CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosisocrelizumab, alemtuzumab 및 cladribine 후 CD19 B 세포 재증식: 다발성 경화증에서 SARS-CoV-2 예방 접종에 대한 의미Article Published on 2022-01-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] SARS, 진단, [키워드] Alemtuzumab B cell B-cell CD19 CD20 Cladribine clinical trial Control Controlled determine dosing interval exhibited extension facilitate Frequency inhibit lymphocyte maintain MOST Multiple multiple sclerosis occurred Ocrelizumab Relapse relapsing rituximab SARS-CoV-2 vaccination Seroconversion seroconvert Standard therapy Tablet Treatment Trial vaccination [DOI] 10.1016/j.msard.2021.103448 PMC 바로가기 [Article Type] Article
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases면역 매개 염증성 류마티스 질환 환자에서 SARS-CoV-2에 대한 mRNA 백신에 대한 면역 반응Article Published on 2022-01-012022-09-12 Journal: RMD Open [Category] SARS, 진단, [키워드] abatacept age Autoimmune Autoimmune diseases B-cell CD4 CD8 Cellular immune response cellular response Cellular responses correlated COVID-19 cumulative deleterious effects demonstrated depleting dose drug Effect Efficacy elicited Gender glucocorticoid healthy controls humoral humoral responses identify immune response immune system immune system diseases Immune-mediated Immunosuppression immunotherapies infections Inflammatory introduced investigated leflunomide methotrexate mRNA mRNA vaccine mRNA vaccines naïve Patient patients with SARS-CoV-2 phase III trial preserved receiving reduce reduced responders response rheumatic disease rituximab SARS-CoV-2 SARS-CoV-2 vaccine selected Seroconversion seroconversion rate T-cell immune response T-lymphocyte subsets the vaccine Therapies therapy titre treated two-dose regimen vaccination Vaccine were excluded [DOI] 10.1136/rmdopen-2021-001898 PMC 바로가기 [Article Type] Article
COVID-19 outcomes in persons with multiple sclerosis treated with rituximab리툭시맙으로 치료받은 다발성 경화증 환자의 COVID-19 결과Article Published on 2022-01-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, [키워드] Admission age average B-cell Course COVID-19 COVID-19 pandemic demonstrated Desaturation Deterioration disease dose evaluated expired feature Fever group hospital Hospitalization ICU immunosuppressive therapies Infection interval less lower dose Mild Multiple multiple sclerosis neurological outcome Oxygen therapy patients preventive measures Progressive ranged Reactivation receiving risk rituximab RTX SARS-CoV-2 sclerosis secondary severe COVID-19 severe disease therapy treated viral reactivation [DOI] 10.1016/j.msard.2021.103371 PMC 바로가기 [Article Type] Article
Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters리툭시맙 치료 환자에서 SARS-CoV-2 백신 접종의 면역원성: 시기 및 면역학적 매개변수의 영향Article Published on 2022-01-012022-09-12 Journal: Clinical immunology (Orlando, Fla.) [Category] MERS, SARS, 진단, [키워드] anti-SARS-CoV-2 anti-Spike IgG antibody asked Autoimmune diseases B cell B cells Characteristics correlated COVID-19 Effect Hypogammaglobulinemia IgG IgM immune immune response immune system immunogenicity impair median time medications parameter Patient pre-vaccination recruited reduce reduced respond responses Rheumatic diseases rituximab RTX SARS-CoV-2 vaccination shown significantly therapeutic option therapy titers of IgG treated patient vaccination Vaccines [DOI] 10.1016/j.clim.2021.108897 PMC 바로가기 [Article Type] Article
Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281Mungmunpuntipantip et al.에 대한 답변 "SARS CoV-2 백신과 리툭시맙" 관절 뼈 척추 2021;88:105281Comment Published on 2022-01-012022-09-12 Journal: Joint bone spine [Category] MERS, SARS, 진단, [키워드] Abstract bone COVID rituximab spine Vaccine [DOI] 10.1016/j.jbspin.2021.105283 PMC 바로가기 [Article Type] Comment
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continuesCOVID-19 대유행이 계속되는 동안 모발 세포 백혈병의 진단 및 치료Review Published on 2022-01-012022-09-12 Journal: Blood reviews [Category] 변종, 진단, 치료법, [키워드] Avoiding B-cell BRAF BRAF inhibitor Chemotherapy Cladribine Complete COVID-19 COVID-19 pandemic COVID-19 vaccination Dabrafenib disease driven by Efficacy Hairy cell Hairy cell leukemia Ibrutinib indolent leukemia malignancy Minimal residual disease Moxetumomab pasudotox Mutation patients persistence Prevent purine remained rituximab T-cells Toxicity Trametinib treated Treatment unique Vemurafenib [DOI] 10.1016/j.blre.2021.100888 PMC 바로가기 [Article Type] Review
SARS CoV-2 vaccine AND rituximab. Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven Joint Bone Spine. 2021;88:105258SARS CoV-2 백신 및 리툭시맙. Verhoeven Joint Bone Spine의 "SARS CoV-2 백신 및 리툭시맙, 시기가 더 나은 백신 반응을 위한 열쇠일 것"에 대한 논평. 2021;88:105258Comment Published on 2022-01-012022-09-12 Journal: Joint bone spine [Category] SARS, 진단, [키워드] Abstract bone Comment rituximab SARS CoV-2 spine Vaccine [DOI] 10.1016/j.jbspin.2021.105281 PMC 바로가기 [Article Type] Comment
Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment Case reports항-CD20 단일클론항체 치료를 받는 환자에서 장기간 바이러스 양성으로 인한 재발성 코로나바이러스 질환 2019(COVID-19) 폐렴 사례 보고Case Reports Published on 2021-12-302022-09-12 Journal: Medicine [Category] SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration anti-CD20 Antibody Response Case report case sery cause Chain Reaction convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 coronavirus disease 2019 pneumonia COVID pneumonia COVID-19 COVID-19 patient Health health problem hematological Humoral immunity immune system lack life-threatening malignancies malignancy monoclonal antibody monoclonal antibody therapy monoclonal antibody treatment Novel coronavirus obinutuzumab outbreak pathophysiology Patient patients patients with COVID-19 performed Pneumonia polymerase chain polymerase chain reaction Polymerase chain reaction test positive Prolonged prolonged viral shedding receiving rituximab severe acute respiratory syndrome Coronavirus suggested the disease Therapies therapy treated viral shedding [DOI] 10.1097/MD.0000000000028470 PMC 바로가기 [Article Type] Case Reports
Cerebral lesions in hematological malignancies: a case reportCase Report Published on 2021-12-202024-09-02 Journal: Journal of Medical Case Reports [Category] 대상포진, [키워드] Case report Demyelination JC virus PML rituximab [DOI] 10.1186/s13256-021-03196-4 PMC 바로가기 [Article Type] Case Report
Recurrent COVID ‐19 infection in a case of rituximab‐induced hypogammaglobulinaemiaCase Report Published on 2021-12-072022-10-29 Journal: Respirology Case Reports [Category] COVID-19, [키워드] classical complications Computed tomography COVID COVID‐19 COVID‐19 infection COVID‐19 CT scan detectable elicit feature hypogammaglobulinaemia immune response Immunity immunodeficiency increased risk Infection infections lack Live attenuated vaccine natural immune response Patient patients polymerase chain positive re‐infection Recurrent recurrent COVID‐19 reverse transcription rituximab robust RT‐PCR RT‐PCR test SARS‐CoV‐2 the antibody response Thorax Vaccine while [DOI] 10.1002/rcr2.891 PMC 바로가기 [Article Type] Case Report